Merck. has filed a patent for novel compounds that inhibit Nav1.8 channel activity, potentially useful in treating pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. The patent claims a composition comprising a specific compound of structural Formula I. GlobalData’s report on Merck gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Merck & Co Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Merck, Human telomerase RT biomarker was a key innovation area identified from patents. Merck's grant share as of September 2023 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20230312528A1) describes a composition comprising a first compound and a second compound. The first compound is a specific chemical compound with a defined structure, and it can be either unsubstituted or substituted with certain substituents. The second compound is a calcium channel antagonist, which can be selected from a list of specific compounds including amlodipine, diltiazem, felodipine, gabapentin, isradipine, nicardipine, nifedipine, nisoldipine, pregabalin, verapamil, and ziconotide. The composition can be in the form of a pharmaceutically acceptable salt.

The patent claims cover various embodiments of the composition, including different combinations of the first and second compounds. The first compound can be selected from a specific list of compounds, and the second compound can be any of the calcium channel antagonists mentioned. The patent also describes methods of using the composition to treat various disorders, including nociception, osteoarthritis, peripheral neuropathy, inherited erythromelalgia, multiple sclerosis, asthma, itch, atopy, allergic dermatitis, contact dermatitis, renal failure, cholestasis, pruritus, migraine, neurodegeneration following ischemia, epilepsy, and many others.

The patent provides specific examples of the first compound and the second compound, as well as specific combinations of the two compounds. For example, one embodiment of the composition includes the first compound (S)-N-((R)-(3-chlorophenyl)(4-(trifluoromethoxy)phenyl)-methyl)-2-oxoimidazolidine-4-carboxamide and the second compound gabapentin or pregabalin. Other embodiments include different combinations of the first and second compounds.

Overall, the patent describes a composition and its use for the treatment of various disorders. The composition includes a specific compound and a calcium channel antagonist, and it can be formulated as a pharmaceutically acceptable salt. The patent claims cover different combinations of the compounds and provide examples of specific compounds and their combinations.

To know more about GlobalData’s detailed insights on Merck, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies